Literature DB >> 24597872

Steroid receptors aplenty in prostate cancer.

Nima Sharifi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24597872     DOI： 10.1056/NEJMcibr1315706

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Corticosteroids in the management of prostate cancer: a critical review.

Authors:  Chukwuma Ndibe; Christopher G Wang; Guru Sonpavde
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 2.  The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.

Authors:  Jieping Hu; Qingke Chen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

Review 3.  Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Authors:  Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-29       Impact factor: 4.292

4.  Rationing medical education.

Authors:  Kieran Walsh
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

Review 5.  Androgen Signaling in Prostate Cancer.

Authors:  Charles Dai; Hannelore Heemers; Nima Sharifi
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 6.  Metabolic syndrome in prostate cancer: impact on risk and outcomes.

Authors:  Fatima H Karzai; Ravi A Madan; William L Dahut
Journal:  Future Oncol       Date:  2016-04-12       Impact factor: 3.404

Review 7.  The evolving role of enzalutamide on the treatment of prostate cancer.

Authors:  Rosa Nadal; Joaquim Bellmunt
Journal:  Future Oncol       Date:  2016-02-03       Impact factor: 3.404

8.  Emerging mechanisms of enzalutamide resistance in prostate cancer.

Authors:  Frank Claessens; Christine Helsen; Stefan Prekovic; Thomas Van den Broeck; Lien Spans; Hendrik Van Poppel; Steven Joniau
Journal:  Nat Rev Urol       Date:  2014-09-16       Impact factor: 14.432

Review 9.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

10.  Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation.

Authors:  Jianneng Li; Michael Berk; Mohammad Alyamani; Navin Sabharwal; Christopher Goins; Joseph Alvarado; Mehdi Baratchian; Ziqi Zhu; Shaun Stauffer; Eric A Klein; Nima Sharifi
Journal:  Sci Transl Med       Date:  2021-05-26       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.